title: Iron status and survival in diabetic patients with coronary artery disease.
abstract: OBJECTIVE
  To investigate the impact of iron status on survival in patients with type 2 diabetes and coronary artery disease (CAD).
  
  
  METHODS
  Serum ferritin, transferrin saturation (Tsat), and soluble transferrin receptor (sTfR) were measured in 287 patients with type 2 diabetes and stable CAD (65 ± 9 years of age, 78% men).
  
  
  RESULTS
  During a mean follow-up of 45 ± 19 months, there were 59 (21%) deaths and 60 (21%) cardiovascular hospitalizations. Both serum ferritin and sTfR strongly predicted 5-year all-cause mortality rates, independently of other variables (including hemoglobin, measures of renal function, inflammation, and neurohormonal activation). There was an exponential relationship between sTfR and mortality (adjusted hazard ratio [HR] per 1 log mg/L: 4.24 [95% CI 1.43-12.58], P = 0.01), whereas the relationship between ferritin and mortality was U-shaped (for the lowest and the highest quintiles vs. the middle quintile [reference group], respectively: adjusted HR 7.18 [95% CI 2.03-25.46], P = 0.002, and adjusted HR 5.12 [1.48-17.73], P = 0.01). Similar patterns were observed for the composite outcome of all-cause mortality or cardiovascular hospitalization, and in these multivariable models, low Tsat was related to unfavorable outcome.
  
  
  CONCLUSIONS
  Both low and high serum ferritin (possibly reflecting depleted and excessive iron stores, respectively) along with high serum sTfR (reflecting reduced metabolically available iron) identify patients with type 2 diabetes and CAD who have a poor prognosis.
authors.affiliation: Corresponding author: Ewa A. Jankowska, ewa.jankowska@umed.wroc.pl.
authors.forename: Beata
authors.initials: B
authors.lastname: Ponikowska
authors.forename: Tomasz
authors.initials: T
authors.lastname: Suchocki
authors.forename: Bartlomiej
authors.initials: B
authors.lastname: Paleczny
authors.forename: Martyna
authors.initials: M
authors.lastname: Olesinska
authors.forename: Slawomir
authors.initials: S
authors.lastname: Powierza
authors.forename: Ludmila
authors.initials: L
authors.lastname: Borodulin-Nadzieja
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Reczuch
authors.forename: Stephan
authors.initials: S
authors.lastname: von Haehling
authors.forename: Wolfram
authors.initials: W
authors.lastname: Doehner
authors.forename: Stefan D
authors.initials: SD
authors.lastname: Anker
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
authors.forename: Ewa A
authors.initials: EA
authors.lastname: Jankowska
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002423:Cause of Death / Q000639:trends; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000401:mortality*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000401:mortality*; D005260:Female; D005293:Ferritins / Q000097:blood*; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007501:Iron / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D011044:Poland / Q000453:epidemiology; D011379:Prognosis; D015996:Survival Rate / Q000639:trends; D013997:Time Factors
chemical_list: D015415:Biomarkers; D005293:Ferritins; D006442:Glycated Hemoglobin; D007501:Iron